...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

Agreed Fuzzy, one would hope that eventually DM we get tired of his lack of management business success and realize he needs to recruit top end experienced biotech managment and move both Zenith and RVX to the next level for getting a major deal and proper non dilutive financing because it aint happening with him at the helm!!,  You listening Don, how long you going to wait this out....

Share
New Message
Please login to post a reply